about
Antimicrobial safety: focus on fluoroquinolonesThe pharmacokinetics and pharmacodynamics of the carbapanemes: focus on doripenemApplication of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhiOptimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosaProtection Afforded by Fluoroquinolones in Animal Models of Respiratory Infections with Bacillus anthracis, Yersinia pestis, and Francisella tularensis.Moxifloxacin pharmacokinetic profile and efficacy evaluation in empiric treatment of community-acquired pneumonia.A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics?Population pharmacokinetic model for gatifloxacin in pediatric patients.Influence of pharmacokinetics/pharmacodynamics of antibacterials in their dosing regimen selection.Pharmacokinetics and pharmacodynamics of antibacterial agents.Trimethoprim and enterococci in urinary tract infections: new perspectives on an old issue.Pharmacological rationale for antibiotic treatment of intra-abdominal infections.An alternate pathophysiologic paradigm of sepsis and septic shock: implications for optimizing antimicrobial therapy.Can Pharmacokinetic and Pharmacodynamic Principles Be Applied to the Treatment of Multidrug-Resistant Acinetobacter?Continuing education: alternative approaches to optimizing antimicrobial pharmacodynamics in critically ill patients.Pharmacological aspects of the antibiotics used for urological diagnostic procedures.Predicting and preventing antimicrobial resistance utilizing pharmacodynamics: part II Gram-negative bacteria.A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii.Population pharmacokinetics and target attainment analysis of moxifloxacin in patients with diabetic foot infections.Pharmacodynamics of teicoplanin against MRSA.Levofloxacin dosing regimen in severely morbidly obese patients (BMI ≥40 kg/m(2)) should be guided by creatinine clearance estimates based on ideal body weight and optimized by therapeutic drug monitoring.
P2860
Q28255152-2CB20A87-8272-414E-BDFC-E83AE9A39FEFQ28289744-716BE6A6-CE0D-4D86-9B02-E24E7A3234C3Q33769931-48B67609-CB3F-4809-A60B-9D9588009BEEQ34228382-36B0AC1B-88FA-49B6-B712-2975696C4700Q34368520-A43310CF-373C-4C58-AB46-2DD2B061C56DQ35168927-844BD61B-63D1-414B-954F-54CECD032C34Q35617587-E4BCB444-EF3B-47D5-9A82-A86D5DD269F4Q35758967-F39B6F1A-A602-46A2-8E94-07CDC8E6F7E4Q36505518-6F00677F-CD70-47B7-963C-EDA0BD1EE4E3Q36911111-892DADFE-AF09-443D-9F0A-8DE161DCC35BQ37137221-F04B0297-DE45-4A32-A23E-678419F4DC46Q37557851-1B969C57-182B-4829-8D22-ECA8FAB56136Q37563029-9F2400B8-2B37-4DCC-9D4B-84F5C6FB527CQ37838126-10AEF094-F941-4B9E-9763-AD99D2D293CEQ37867260-D5CFB7B3-4194-481B-B77B-971A729DE9E7Q38253258-9E07894C-9C82-4D39-B1F7-62AEB9F3EFAEQ39293585-5FF61CF7-A94A-429B-9074-E10F5F31CA25Q40360159-8C991767-AEB4-4EAC-A212-33943D5BCD40Q41534755-FC0B2A0F-39C9-4E48-BAD4-393D10A847F0Q41992893-8F0F2E82-892B-4908-A636-E08624D5E370Q44455948-1B9CF535-17C7-43A5-B7D2-8E096FAF7054
P2860
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Clinical pharmacodynamics of quinolones.
@ast
Clinical pharmacodynamics of quinolones.
@en
type
label
Clinical pharmacodynamics of quinolones.
@ast
Clinical pharmacodynamics of quinolones.
@en
prefLabel
Clinical pharmacodynamics of quinolones.
@ast
Clinical pharmacodynamics of quinolones.
@en
P2093
P1476
Clinical pharmacodynamics of quinolones.
@en
P2093
Paul G Ambrose
Robert C Owens
Sujata M Bhavnani
P304
P356
10.1016/S0891-5520(03)00061-8
P577
2003-09-01T00:00:00Z